NRx Pharmaceuticals Yönetim

Yönetim kriter kontrolleri 2/4

NRx Pharmaceuticals CEO'su Jonathan Javitt, Mar2022 tarihinde atandı, in görev süresi 2.83 yıldır. in toplam yıllık tazminatı $ 630.20K olup, şirket hissesi ve opsiyonları dahil olmak üzere 95.6% maaş ve 4.4% ikramiyelerden oluşmaktadır. şirketin hisselerinin 12.58% ine doğrudan sahiptir ve bu hisseler € 6.83M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 2.8 yıl ve 1.1 yıldır.

Anahtar bilgiler

Jonathan Javitt

İcra Kurulu Başkanı

US$630.2k

Toplam tazminat

CEO maaş yüzdesi	95.6%
CEO görev süresi	2.8yrs
CEO sahipliği	12.6%
Yönetim ortalama görev süresi	2.8yrs
Yönetim Kurulu ortalama görev süresi	1.1yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Jonathan Javitt'un ücretlendirmesi NRx Pharmaceuticals'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	-US$20m
Jun 30 2024	n/a	n/a	-US$25m
Mar 31 2024	n/a	n/a	-US$26m
Dec 31 2023	US$630k	US$603k	-US$30m
Sep 30 2023	n/a	n/a	-US$36m
Jun 30 2023	n/a	n/a	-US$39m
Mar 31 2023	n/a	n/a	-US$37m
Dec 31 2022	US$874k	US$867k	-US$40m
Sep 30 2022	n/a	n/a	-US$60m
Jun 30 2022	n/a	n/a	-US$88m
Mar 31 2022	n/a	n/a	-US$81m
Dec 31 2021	US$377k	US$275k	-US$93m
Sep 30 2021	n/a	n/a	-US$108m
Jun 30 2021	n/a	n/a	-US$76m
Mar 31 2021	n/a	n/a	-US$76m
Dec 31 2020	US$615k	US$275k	-US$52m

Tazminat ve Piyasa: Jonathan 'nin toplam tazminatı ($USD 630.20K ), German pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 464.61K ).

Tazminat ve Kazançlar: Jonathan 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Jonathan Javitt (67 yo)

2.8yrs

Görev süresi

US$630,198

Tazminat

Dr. Jonathan C. Javitt, M.D., M.P.H. is the Interim Chief Executive Officer of NRx Pharmaceuticals, Inc. since October 11, 2024 and is it's Chief Scientist Officer since March 9, 2022. He is a Co-Founder o...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Jonathan Javitt	Co-Founder	2.8yrs	US$630.20k	12.58% € 6.8m
Richard Narido	Treasurer	no data	US$298.02k	0% € 0
Michael Abrams	Chief Financial Officer	no data	Veri yok	Veri yok
Riccardo Panicucci	Chief Manufacturing & Technology Officer	4yrs	US$240.00k	Veri yok
Suzanne Messere	Investor Relations	no data	Veri yok	Veri yok
Philip Lavin	Chief Methodologist	no data	Veri yok	Veri yok
Matthew Duffy	Chief Business Officer & Co-CEO of Hope Therapeutics	1.8yrs	Veri yok	Veri yok

2.8yrs

Ortalama Görev Süresi

62yo

Ortalama Yaş

Deneyimli Yönetim: B1Q 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.8 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Jonathan Javitt	Co-Founder	1.1yrs	US$630.20k	12.58% € 6.8m
Chaim Hurvitz	Independent Director	3.7yrs	US$52.50k	1.84% € 996.7k
Patrick Flynn	Independent Director	3.7yrs	US$67.50k	0.49% € 265.7k
Janet Rehnquist	Independent Director	1.1yrs	Veri yok	Veri yok
Dennis McBride	Independent Director	less than a year	Veri yok	Veri yok

1.1yrs

Ortalama Görev Süresi

67yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: B1Q 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilmiyor ( 1.1 yıllık ortalama görev süresi), bu da yeni bir yönetim kurulu olduğunu gösteriyor.

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2025/01/08 03:12
Gün Sonu Hisse Fiyatı	2024/10/25 00:00
Kazançlar	2024/09/30
Yıllık Kazançlar	2023/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.

Analist Kaynakları

NRx Pharmaceuticals, Inc. 3 Bu analistlerden 3, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Edward Woo	Ascendiant Capital Markets LLC
Jason Kolbert	D. Boral Capital LLC.
Vernon Bernardino	H.C. Wainwright & Co.

NRx Pharmaceuticals Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

NRx Pharmaceuticals, Inc. Announces Chief Financial Officer Changes

NRx Pharmaceuticals, Inc. Announces Chief Executive Officer Changes

NRx Pharmaceuticals, Inc., Annual General Meeting, Oct 08, 2024

NRx Pharmaceuticals, Inc. Announces Resignation of Stephen Willard as Chief Executive Officer

NRx Pharmaceuticals, Inc. Appoints Dennis McBride to Its Board of Directors

Less than half of directors are independent

Recent updates

NRx Pharmaceuticals, Inc. Files Initial Section of U.S. New Drug Application to the FDA for NRX-100 (IV Ketamine) for the Treatment of Suicidal Depression

NRx Pharmaceuticals, Inc. Announces Chief Financial Officer Changes

NRx Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 14, 2024

NRx Pharmaceuticals, Inc. Announces Chief Executive Officer Changes

NRx Pharmaceuticals, Inc., Annual General Meeting, Oct 08, 2024

NRx Pharmaceuticals, Inc. Announces Resignation of Stephen Willard as Chief Executive Officer

NRx Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 14, 2024

NRx Pharmaceuticals Receives Letter from the Listing Qualifications Staff of the Nasdaq Regarding Market Value of Listed Securities

HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. Announce Alignment with FDA on Pediatric Study Plan for NRX-100 (ketamine)

NRx Pharmaceuticals, Inc. to Proceed with Two New Drug Applications in 2024

NRx Pharmaceuticals, Inc. Appoints Dennis McBride to Its Board of Directors

NRx Pharmaceuticals, Inc. Presents Landmark Trial of Nrx-101 in Suicidal Bipolar Depression At the American Society of Clinical Psychopharmacology Annual Meeting: Nrx-101 Is the First Oral Antidepressant Demonstrated to Reduce Suicidality in Bipolar Depression

NRx Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 14, 2024

NRx Pharmaceuticals, Inc. Announces Final Clinical Trial Results

NRx Pharmaceuticals, Inc. Announces Promising Findings in Phase 2B/3 Clinical Trial of Nrx-101 Vs. Lurasidone for Treatment of Suicidal Bipolar Depression

NRx Pharmaceuticals, Inc. Announces Promising Findings in Phase 2B/3 Clinical Trial of Nrx-101 Vs. Lurasidone for Treatment of Suicidal Bipolar Depression

NRx Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $2.0031 million.

NRx Pharmaceuticals, Inc. has filed a Follow-on Equity Offering.

NRx Pharmaceuticals, Inc. has filed a Follow-on Equity Offering.

NRx Pharmaceuticals, Inc. Announces New Data on NRX-101 Demonstrating No Damage to Intestinal and Vaginal Flora in Validated Rodent Models Compared to Standard Antibiotics

NRx Pharmaceuticals, Inc. Announces Development of New, Proprietary Formulation of HTX-100 (IV Ketamine)

NRx Pharmaceuticals, Inc. Announces Data-Lock of Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression

NRx Pharmaceuticals Announces Reverse Stock Split to Maintain Nasdaq Listing

NRx Pharmaceuticals, Inc. to Report Q4, 2023 Results on Mar 28, 2024

Less than half of directors are independent

NRX Pharmaceuticals Announces Last Patient, Last Visit in Its Phase 2B/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression

NRx Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $1.5 million.

NRx Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $1.5 million.

Panel Grants NRx Pharmaceuticals Request for an Exception to Nasdaq Listing Rules Until April 16, 2024, to Demonstrate Compliance with the Rule

NRx Pharmaceuticals, Inc. Announces Completion of Enrollment of Its Phase 2b/3 Trial of NRx-101 in Suicidal Treatment Resistant Bipolar Depression

NRx Pharmaceuticals, Inc. Announces FDA Qualified Infectious Disease Product and Fast Track Designation of NRX-101 in Complicated Urinary Tract Infection and Pyelonephritis

NRx Pharmaceuticals Demonstrates Compliance with Nasdaq MVLS Standard

Nrx Pharmaceuticals Announces Election of Janet Rehnquist to Its Board of Directors

NRx Pharmaceuticals, Inc. Announces FDA Clearance of its Investigational New Drug (IND) Application for NRX-101 in the Treatment of Complicated Urinary Tract Infections

NRx Pharmaceuticals, Inc., Annual General Meeting, Dec 19, 2023

NRx Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 14, 2023

NRx Pharmaceuticals Announces Further Alignment with FDA on Initiation of Registrational Trials for NRX-101 in the Treatment of Chronic Pain

NRx Pharmaceuticals Receives Formal Notice from the Listing Qualifications Staff of Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement

NRx Pharmaceuticals Announces Strategic Acceleration of its Plans to Develop Commercial Form of NRX-100 (intravenous ketamine) to Treat Acute Depression and Suicidality

NRx Pharmaceuticals Announces FDA Permission to Proceed on Investigational New Drug (IND) Application for NRX-101 to Treat Chronic Pain

NRX Pharmaceuticals, Inc. Appoints Richard Narido, as Principal Financial Officer and Principal Accounting Officer

NRx Pharmaceuticals, Inc. Announces New Data That Demonstrates Potent in Vitro Activity of NRx-101

NRx Pharmaceuticals Announces Submission of an Investigational New Drug Application for NRX -101 in the Treatment of Chronic Pain

NRx Pharmaceuticals, Inc. announced that it expects to receive $1.2 million in funding

NRx Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 14, 2023

NRx Pharmaceuticals Receives Written Notification from Nasdaq Regarding Non-Compliance with Nasdaq Listing Rule 5450(b)(2)(A) – Market Value of Listed Securities

NRx Pharmaceuticals, Inc. Reports Minutes of U.S. Food and Drug Administration Meeting on Development of NRX-101 to Treat Severe Bipolar Depression in Patients with Suicidality

NRx Pharmaceuticals, Inc. Provides Progress Update on Interactions with the FDA regarding Path to NDA Submission for NRX-101

NRx Pharmaceuticals, Inc. Initiates Phase 3 Trial Treating Patients with Bipolar Depression with Acute Suicidality - First Clinical Site Contracted

Relief Therapeutics Holding AG (SWX:RLF) acquired ZYESAMI of NRx Pharmaceuticals, Inc.

Relief Therapeutics Holding AG and NRx Pharmaceuticals, Inc. Announces Close of Definitive Settlement Agreements

NRx Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 14, 2022

NRx Pharmaceuticals, Inc. Produces First Phase 3-stage NRX-101 Drug Made Using Commercial Process

NRx Pharmaceuticals, Inc. announced that it has received $10 million in funding

NRx Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 15, 2022

NRx Pharmaceuticals Receives Non-Compliance Letter from Nasdaq

NRx Pharmaceuticals, Inc. Announces the Appointment of Stephen Willard as its Chief Executive Officer

Nrx Pharmaceuticals, Inc. Announces FDA Declines Emergency Use Authorization for Zyesami® (Aviptadil) for Subgroup of Patients with Critical Covid-19 At Immediate Risk of Death from Respiratory Failure Despite Treatment with Approved Therapy, Including Remdesivir

High number of new and inexperienced directors

NRx Pharmaceuticals, Inc. Announces Class Action Suit Against the Company Dismissed

Nrx Pharmaceuticals, Inc. Announces Director Resignation

NRx Pharmaceuticals, Inc., Annual General Meeting, Jul 18, 2022

NRx Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Denied for aviptadil

NRx Pharmaceuticals, Inc. Provides Update on Breakthrough Therapy Designation Request for ZYESAMI® (Aviptadil)

NRx Pharmaceuticals Appoints Seth Van Voorhees as Chief Financial Officer, Effective June 13, 2022

Co-Founder recently bought €54k worth of stock

NRx Pharmaceuticals, Inc. Announces Executive Changes

NRx Pharmaceuticals, Inc. Announces Data Safety Monitoring Board (DSMB) Update on U.S. National Institutes of Health (NIH) Study of ZYESAMI® (aviptadil) in Critical COVID-19

CEO Tazminat Analizi